About ACELYRIN
ACELYRIN is a company based in Los Angeles (United States) founded in 2020 by Shao Lee Lin. ACELYRIN has raised $550 million across 3 funding rounds from investors including Marshall Wace, TD Securities and Citadel. ACELYRIN has completed 1 acquisition, including ValenzaBio. ACELYRIN offers products and services including Izokibep and Lonigutamab. ACELYRIN operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Los Angeles, United States
- Founders Shao Lee Lin
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website acelyrin.com
- Social LinkedIn X
- Legal Name Acelyrin, Inc.
- Total Equity Funding$550M (USD)
in 3 rounds
- Latest Funding Round$300M (USD), Series C
Sep 2022
- InvestorsMarshall Wace
& 13 more
- Investments & Acquisitions
Products & Services of ACELYRIN
ACELYRIN offers a comprehensive portfolio of products and services, including Izokibep and Lonigutamab.
Investigational drug targeting immunology diseases for patient treatment.
Potential therapy for unmet needs in immunology applications.
Funding Insights of ACELYRIN
ACELYRIN has successfully raised a total of $550M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $300 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $550M
- Total Rounds 3
- Last Round Series C — $300M
- Investors Count 14
All 3 funding rounds of ACELYRIN with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | $300M | Series C | – | Access Industries | |
| Nov 2021 | $250M | Series B | – | Westlake Village Biopartners, Citadel | |
| Dec 2020 | – | Series A | – | Westlake Village Biopartners | – |
14 investors in total: 14 institutional.
Investors in ACELYRIN
ACELYRIN has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Marshall Wace, TD Securities and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | matrixcapitalmanagement.tcc.mode | - | |
Westlake BioPartners is engaged in biotech venture capital investment. | – | westlakebio.com | Westlake Village, United States | |
Venture capital firm focused on life science and technology sectors | – | decheng.com | Shanghai, China | |
Long-short equity strategies are managed through specialized hedge funds. | 1997 | mwam.com | London, United Kingdom | |
Venture capital funding is provided by Samsara BioCapital in California. | – | samsaracap.com | Palo Alto, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Investment and holding company controlled by Len Blavatnik | – | accessindustries.com | New York, United States | |
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States |
Investor details for ACELYRIN
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ACELYRIN
11 people are tracked at ACELYRIN (10 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Shao Lee Lin | Co-Founder & CEO | Leadership |
Anita Grover | Vice President, Program Team Lead | Leadership |
Martha L Cruz | Executive Director Alliance Management | Leadership |
Ken Lock | Chief Commercial Officer | Leadership |
Lauren Szuter | Director, Pharmacovigilance Safety Scientist | Leadership |
Wei Zhou | Vice President - Head Of External Manufacturing, Supply Chain, And Real Estate | Leadership |
Amol Kamboj | Senior Medical Director, Clinical Development | Leadership |
James Gould | Associate Director Data Managment | Leadership |
Haideh Tehrani | Sr. Director, Head CMC Quality | Leadership |
Xiaorui Yang | Associate Director, Biologics Drug Substance | Leadership |
James Lee | JCL Consulting, Principal (it Program Management) | Team |
Complete people profiles for ACELYRIN
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ACELYRIN
ACELYRIN has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ValenzaBio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Treatments for autoimmune and inflammatory diseases are developed. | valenzabiotech.com | Bethesda, United States | 2019 | Jan 2023 | •••• |
Complete acquisition details for ACELYRIN
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of ACELYRIN
5 dated milestones of ACELYRIN across 3 years, from founding to its latest funding, stage changes and deals.
- Founded ACELYRIN is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $300.0M.
- Acquisition Acquires ValenzaBio.
- IPO Lists on the stock exchange (IPO).
Competitors of ACELYRIN
ACELYRIN operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| septerna.com | 2020 | San Bruno, United States | $250M | – | GPCR drug discovery platform is developed for multiple diseases. | |
| upstreambio.com | 2021 | Waltham, United States | $400M | – | Therapeutics for allergic and inflammatory diseases are developed. | |
| gossamerbio.com | 2017 | San Diego, United States | $330M | 102 | Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer | |
| calcimedica.com | 2006 | San Diego, United States | $76.66M | 11 | CRAC channel inhibitors are developed for inflammatory diseases. |
Detailed competitors of ACELYRIN
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ACELYRIN
Websites that share an audience with ACELYRIN (acelyrin.com).
Websites whose visitors overlap most with ACELYRIN. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biocentury.com | 100% | 85.7K | #514,907 | View details | |
| biopharmadive.com | 85% | 680.7K | #208,628 | View details |
Latest news on Acelyrin
Complete news archive for ACELYRIN
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ACELYRIN
10 companies that operate in the same segment as ACELYRIN (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ACELYRIN
ACELYRIN was founded in 2020.
ACELYRIN is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Shao Lee Lin is the current CEO of ACELYRIN. They have also founded this company.
ACELYRIN is a funded company, having raised a total of $550M across 3 funding rounds to date.
ACELYRIN was established in 2020 and is headquartered in Los Angeles, United States. Operations focus on the biotechnology sector, where therapeutic candidates are developed and commercialized to address severe immunological conditions. Targeted diseases include uveitis, axial spondyloarthritis, hidradenitis suppurativa, and psoriatic arthritis. The company is led by co-founder and CEO Shao Lee Lin.
ACELYRIN's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
ACELYRIN offers Izokibep and Lonigutamab.
ACELYRIN has made 1 acquisition, including ValenzaBio.
ACELYRIN has 14 investors. Key investors include Marshall Wace, TD Securities, Citadel, Orbimed, and RTW Investments.
ACELYRIN operates through Acelyrin, Inc..